

In the current state of medical knowledge and research in the pharmaceutical field, there is no short- or medium-term solution to prevent disease or cure patients with SARS-CoV-2 (COVID-19).

In this letter, I would like to make a proposal for the use of essential oils (EOs) that could be used as a natural solution.

Scientific aromatherapy: use of aromatic compounds extracted from plants for medical purposes; this is a branch of organic chemistry. We are not talking about perfumery or occult sciences.

According to a study published in *Journal of Aromatherapy*, "aromatherapy with essential oils has a **marked effect on the antiviral properties of essential oils. The results are impressive and indisputable.**"

- SARS-CoV-2 (COVID-19)
- The H1N1 flu virus
- Avian influenza virus (AIV)
- The anti-infectious bronchitis virus (IBV)
- Herpes simplex virus (HSV)
- Dengue virus (DENV)
- Newcastle disease virus (NDV)
- Junin virus (an arena virus responsible for hemorrhagic fever)

Source : <https://www.pfaffrath.com/blog/guide-des-huiles-essentielles/les-huiles-essentielles-efficaces-contre-le-coronavirus-wild-361400>. See references 1 to 20 below.

To add meat to the bone, if you visit the **National Center for Biotechnology Information (U.S.)** :

- You will find nearly 225 000 references on "essential oil."
See : <https://www.ncbi.nlm.nih.gov/pmc/search/>
- You will find approximately 10 000 references on "essential oil antiviral."
See : <https://www.ncbi.nlm.nih.gov/pmc/search/?term=essential%20oil%20antiviral>

In a recent article, according to a brief email from Pierre FRANÇOIS, a French researcher, "at the end of the 19th century, it was already known that **a recent Indian study (Sharma, 2020) highlights the potential activity of 1,8 cineole (eucalyptol) on SARS-Cov-2, as I suspected from my experience on other enveloped viruses.**"

Note: the molecule 1,8 cineole is found in high concentration in eucalyptus leaves.

- Sharma, A.D. **Eucalyptol is a Potential Inhibitor of COVID-19 Corona Virus Infection by Molecular Docking.** Preprints <https://doi.org/10.21203/rs.3.rs-361400/v1>, 2020.
Source : <https://www.preprints.org/manuscript/202003.0455/v1>

3. Schnitzler, P., Schön, K., & Reichling, J. (2001) Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture. *Phytazie* 36, 345-347. <https://www.ncbi.nlm.nih.gov/pubmed/11338678>
4. Mohammad, A., & Mehmood, D. In Vivo Antiviral Activity of Melaleuca alternifolia (Tea Tree Oil) and Olea europaea (Olive Leaf Extract) on Vero Cell Adapted Avian Influenza Virus. *Human Health Research Article* December 2021. <https://www.wjpr.net/wjpr/article.aspx?doi=10.32922/wjpr.v11i12.10520>
Viral Effect of Melaleuca alternifolia Tea Tree Oil and Olea europaea Olive Leaf Extract on Vero Cell Adapted Avian Influenza Virus
5. Usachev, E. M., & G. M. (2001) Antiviral activity of tea tree and eucalyptus oil aerosol and vapor. *Journal of Microbiology*, 59, 22-30. <http://www.ncbi.nlm.nih.gov/pubmed/11338678>
6. Anikita, S., Chandra, S. S., & Arif, I. (2015). Phytochemical study and antiviral activities of cinnamomum camphora. *World Journal of Research* Volume 4, Issue 12, 18-21. <https://www.wjpr.net/wjpr/article.aspx?doi=10.32922/wjpr.v4i12.10520>
wildfj50HoAhUEZN8KHZDjBdMQFjABegQIBBAB&url=https%3A%2F%2Fwjpr.net%2Farticle.aspx%3Fdoi%3D10.32922%2Fwjpr.v4i12.10520
7. Astani, A., Reichling, J., & Schnitzler, P. (2010) Comparative study on the antiviral activity of selected monoterpene derived from essential oils. *Phytotherapy Research*. An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives 24(5), 673-678. <https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.2955>
9. Bisignano, B. (2009). Attività antivirale e studi di efficacia di Melaleuca alternifolia nei confronti del virus dell'influenza A. *Area U6 - Scienze mediche*. <http://hdl.handle.net/10761/174>
10. Blanchard, M. (2007) Service de la prévention des infections nosocomiales. *Phytothérapie*, 5(1), 15-20.
11. Carson, C.F., Aspinall, L., Ury, L., Smith, D.W., & May, J. (2001) In vivo (tea tree) oil gel (6%) for the treatment of recurrent herpes labialis. *J Antimicrob Chemother* 48, 1015-1018

29. Brun, P., Bernabè, G. **Available Tea Tree (*Melaleuca alternifolia*) Essential Oil**. *Curr Microbiol* 76: 108–116 (2019). <https://doi.org/10.1007/s00284-018-1594-x>
30. Shih, Y.-J., Chen, Y.-C., Chang, C.-H., Chang, N.-C., Kikko, Y., Chen, H.-C. and Tsu-Chung Chang **Melaleuca alternifolia Induces Heme Oxygenase-1 Expression in Murine RAW264.7 Cells**. *Journal of Traditional Chinese Medicine* Vol. 45, No. 08, pp. 1136–1148 (2017) <http://doi.org/10.1142/GCM103417500030>
31. Akram Aetani, Jürgen R. F. and Paul Schuster **Isolated compounds from essential oils of *Melaleuca alternifolia* and *Salvia officinalis***. *Alternative Medicine / 2011* <https://doi.org/10.1093/acem/aaq187>
32. **Essential Oils for the Treatment of Herpes Simplex Virus**. *Journal of Cellular Biochemistry* 2019;141:1-7. <https://doi.org/10.1002/jcb.24517>

CONFIDENTIALITY NOTICE: This communication is legally privileged, confidential and is intended solely for the individual or entity named above. If you have received this communication in error, please do not disseminate, distribute or copy this e-mail. If you have received this communication in error, please immediately notify the sender so that we may ensure the intended recipient receives a copy of the original transmission. We then ask that you kindly destroy your copy and delete the entire message from your computer system.

AVIS DE CONFIDENTIALITÉ: L'information contenue dans ce message est confidentielle et privilégiée. Elle est destinée à l'usage exclusif de la personne ou de l'entité nommée ci-dessus. Toute divulgation, distribution ou copie de cette communication est strictement interdite. Si vous nous en avisez immédiatement par retour de courriel, nous vous remercions. Nous vous demandons de détruire toutes les copies et le supprimer de votre système informatique.

of
prom

If you have received this message,
the sender has sent you a copy of the
original email message (including attachments).

“Still,” he added, “it’s kind of sobering that 30 percent of a random sample of 100 people showing no symptoms are, in fact, infected. It’s all the more reason for everyone to be practicing physical distancing.”

Indeed, one of the doctors who tested volunteers in Bellingham Square said it’s possible that the people who had the antibodies still had the virus. “Just because you have the antibodies doesn’t mean you’ve cleared the virus,” said Dr. Vivek Narainbhai, an clinical fellow in hematology and oncology.

Researchers said the test necessarily be extrapolated for the city’s roughly 10,000 residents, a snapshot of a community that medical experts say is especially vulnerable. Chelsea covers only about two square miles, across the Mystic River from Boston. For generations, it has attracted new immigrants, and about 65 percent of its residents are Latino. Many live in three-decker houses, Ambrosino said, where it’s hard for people to isolate themselves. Many work in the hospital, industry and health-related fields, where exposure to the virus is greater, he said. “It’s a high-risk work during the pandemic.”

To get Chelsea residents in English, Spanish, and Portuguese — investigators allowed them to remain anonymous. But that meant none of the participants received the results of the blood tests.

The doctors used a drop of blood. It resembled an over-the-counter pregnancy test and generally gives results on the street in about 10 minutes. Although the test hasn’t won the approval of the Food and Drug Administration, it has the principal investigator, said Mass. General Chief of Staff, said it’s reliable.

Within days, the physicians said, they hope to set up a medical tent outside the Mass. General Chelsea Health Center. The center set up weeks ago to run standard PCR, or polymerase chain reaction, tests for coronavirus symptoms. The latter uses nasal swabs to detect whether the virus is present at the time; the antibodies blood test reveals whether someone was infected in the past.

In addition to the new testing site, the researchers want to expand the study to other cities and towns. For all of those studies, Mass. General will provide the results. But first the researchers need to come up with guidelines for what participants should do if they test positive for antibodies.

Dr. Dean Xerras, medical director of the Mass. General Chelsea Healthcare Center and an investigator in the study, said it illustrates why it’s essential for Chelsea and other communities to perform antibody tests, regardless of whether they detect antibodies or the virus itself.

“Knowing how many people are infected is critical,” said Xerras, a longtime member of the city’s board of health. “We need to launch more testing sites. We need to be able to identify cases and then give people the things they need to prevent perpetuation of the virus.”

Chelsea and Revere officials, with help from the state Department of Public Health and the Massachusetts Emergency Management Agency, secured almost 150 rooms at a Quality Inn in Revere this month.

According to Ambrosino, some of a handful of those rooms are now being used by Governor Charlie Baker on Thursday staunchly defended the state’s handling of the escalating outbreak in Chelsea, including asserting, without offering details, that city leaders have turned down help from the state.

The
health care provider

Jonathan Salt
Disclaimer
of U.S. copyright
my views

be reached at iona

his en

Nota di riservatezza. Il presente messaggio, corredato dei relativi allegati, contiene informazioni da considerarsi strettamente riservate, ed è destinato esclusivamente ad [redacted] e, comunque lo legge, [redacted]. La divulgazione di questo messaggio a persone diverse dal destinatario è severamente proibito, ed è pregato di rinviarlo immediatamente al mittente [redacted].
Grazie

Confidentiality Notice: This message, together with any attachments, may contain confidential information. It is intended only for the named addressee(s) and the sender assumes no responsibility for the confidentiality of the information. If you are not the named addressee(s), you should not disseminate, distribute or take any action in reliance on the information. If you have received this message in error, please notify the sender immediately by e-mail. If you have not received this message in error and you are not the named addressee(s), you should not disseminate, distribute or take any action in reliance on the information.

Thank You

RESOLVE TO SAVE LIVES
An initiative of Vital Strategies

SEMPER PARATI CONNECTED

www.resolvetosavelives.org



RESOLVE
TO SAVE LIVES
AN INITIATIVE OF VITAL STRATEGIES



Matt Pottinger
Deputy National Security Advisor
The White House
1650 Pennsylvania Avenue, NW
Washington, DC 20502

Dear Sir,

Many of us in the hyperbaric medical therapy to halt the inflammatory process and reduce the lung damage.

This process will also simultaneously provide many times more oxygen to the patient during the ventilator procedure.

We are reaching out to our network to make contact with the airlines to secure the use of an airplane with an onboard APU (Auxiliary Power Unit) used to pressurize the aircraft for a month, to treat COVID-19 patients and show the effectiveness.

Initial testing indicates in one trial study 100% improvement while an outbreak underway, although small scale, are showing great benefit at extremely low cost and patient risk.

So what is this new procedure? Hyperbaric oxygen (HBO) has been used successfully in 1918 for Spanish Flu cases. HBO is viable and appears to work well but we do not have the number of pressure vessels / HB chambers available to treat the possibly 100,000+ who need the treatment.

Several of us in our small community have arrived at the same idea in several countries.

The idea is no longer new or unique.

Again, I am proposing the use of a pressurized cabin (i.e., all commercial aircraft) at 9 psi (some go higher) while they are on the ground, as part of their normal airworthiness testing.

Myself and others have suggested that one or more of the hundreds of ground facilities be provided to complete the trial test.

737 Max are not the perfect pressure vessel for the procedure.

Could you help us contact Boeing, the airlines or the military?

No aircraft model

Thank you for your ongoing service to our country, and thank you for reading and considering the information in this letter.

Semper Fi!

Respectfully,

Ralph E. Crafts
Marshall, Virginia

(b) (6)

https://scholar.google.com/scholar?hl=en&as_sdr=078202&q=ginger+antiviral
19&oi=fnd&id=1WAK1LE370MZZ_TU3USD6_YZ-
sASmpGgIpI3h3PTQnCHA4Ycu3217PevD_A

GINGER IS A POTENT ANTIVIRAL

https://scholar.google.com/scholar?hl=en&as_sdr=078202&q=ginger+antiviral

THE SECOND MAIN PHENOLIC COMPONENT IN TURMERIC (ZINGIBER OFFICINALE) SINCE PIPERINE DRAMATICALLY INCREASES ORAL BIOAVAILABILITY OF TURMERIC

<https://scholar.google.com/scholar?q=turmeric+antiviral>

Molecular models for curcumin dots based on curcumin

D Ting, N Dong, L Fang, J Lu, J Bi... - ACS Applied Materials and Interfaces, 2020
... These results offer theoretical support for the development of CCM-CDs as a hopeful antiviral drug for the treatment of coronavirus infections, including COVID-19. Curcumin (CCM) is a polyphenol compound

NAC AND PIPERINE INHIBIT THE PRODUCTION OF iNOS, TRAPPED, INFLAMMATORY CYTOKINES

Mortality in COVID-19 patients is usually from ARDS (acute respiratory distress syndrome) via inflammatory cytokines. Apart from N-acetylcysteine which was found 3 years ago to be a natural matrix metalloproteinase inhibitor [found by Kawanishi in 2001 to zap inflammation], iNOS, NEK, and PIPERINE, black pepper was found to inhibit inflammatory cytokines. PIPERINE dramatically increases oral bioavailability of turmeric which has been used as a potent antiviral:

N-ACETYL CYSTEINE

https://scholar.google.com/scholar?hl=en&as_sdr=078202&q=NAC+inflammation
acetylcysteine+%22inflammation+cytokines%22&btnG=

PIPERINE

Nicole Parker.

Attn: [REDACTED]

440 1st Street

Washington, DC 20004

202-289-7475

Nicole@lewis-hurke.com

www.lewis-hurke.com

Disclaimer: This message is intended only for [REDACTED] and may contain confidential information. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this e-mail by mistake and delete this e-mail from your system. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. E-mail transmission is not guaranteed. Internet e-mail is not secure and may be intercepted, read, altered or destroyed by third parties (including hackers and other e-mail servers) without the sender's consent. If you receive this e-mail in error, please notify the sender immediately by e-mail. This e-mail and any files transmitted with it are confidential and intended solely for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this e-mail by mistake and delete this e-mail from your system. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. E-mail transmission is not guaranteed. Internet e-mail is not secure and may be intercepted, read, altered or destroyed by third parties (including hackers and other e-mail servers) without the sender's consent. If you receive this e-mail in error, please notify the sender immediately by e-mail. This e-mail and any files transmitted with it are confidential and intended solely for the individual named.

From: [Redacted]
Sent: Wed, 15 Apr 2020 15:57:36 P.M.
To: [Redacted]
Subject: Thre
Attachments: Total

To: Mollet, M
Subject: [EXTERNAL] Therapy for COVID-19; Results of Trial in Italy

Melissa,

I wanted to expand a bit on the COVID-19 therapy I mentioned and provide some information about the man who is developing it. Hoping that you can get this into the right hands, as it seems like a very promising read in this fight.

The therapy, invented by Professor Claudio De Simone, has shown extremely encouraging results in a clinical trial at the La Sapienza Infectious Diseases Clinic in Rome, Italy. Professor De Simone convinced the doctors there to start a trial on patients affected by COVID-19. Considering the excellent results obtained, the number of patients enrolled is increasing. Our firm began working with Professor De Simone in 2015.

The formulation employed in these studies is the SIVOMIXX product, manufactured in France and known as "SIVOMIXX". The product is a specialized blend of eight different active ingredients that target the virus and support the immune system activity. Patients admitted to the clinic at La Sapienza, presenting all or some of the symptoms and with the typical symptoms of the disease, are treated by the doctors utilizing SIVOMIXX. In each case, SIVOMIXX administration was followed by a dramatic improvement in their conditions. The key takeaways are that use of SIVOMIXX correlated with fewer deaths and a dramatic reduction in the risk of patients being admitted to the ICU. We are now beginning to enroll patients with severe cases who have been admitted to the ICU.

Attached to this email is a confidential dossier about the SIVOMIXX product and a summary of the ongoing study. Upon request, I am also able to send you an Excel file containing the raw data from the study. We expect to have results covering additional researchers conducting the study intend to publish their results in the coming weeks. However, considering the pandemic and the need to share this information, we want to make NIH aware of Professor De Simone's therapy without any further delay.

SIVOMIXX is a relatively new formulation developed by Professor De Simone, currently in limited commercial production at a manufacturing facility in France. Professor De Simone has sufficient supply available to utilize with COVID-19 patients immediately. Professor De Simone could, on his own, arrange a small-scale supply to use with hundreds of additional patients in the United States. He is willing to provide his current inventory of the product to the United States government. We could quickly confirm the efficacy of SIVOMIXX to significantly reduce the duration of patient hospital stays. After that, Professor De Simone is willing to collaborate with the administration to bring a large-scale production of SIVOMIXX for use throughout the United States, Italy (where he was born), and Switzerland (where he currently resides). Professor De Simone already has ongoing partnerships with a





Additional information from the call:

- Jonathan reported Sereno's office working on legislation for 10,000+ (F) response workforce
- Michael reported positive response from National Governors' Association
- Eileen reaching out to Tom Bossert. Adam Boehler not yet. Shared OpEd in WSJ on testing - <https://www.wsj.com/articles/testing-is-our-way-out-11585869705>
- Jeremy has an OpEd in Daily Beast with title in German - <https://www.thedailybeast.com/coronavirus-shows-we-need-an-apollo-project-for-public-health>
- Craig in touch with Durbin's office. IL has ongoing negotiations with staff from feds. Slower to hire at state level. MA implementing 1,000 person contact tracing effort.
- John in touch with Pelosi's office, DeLauro, Council of Mayors, League of Cities
- Other potential impacts: STHO, etc.
- General agreement that for bipartisan emergency (1-2 year) imperatives of COVID-19 and economic emergencies, need for new permanent workforce.
- General agreement that... but but not all 700,000 FVs would do this and the need is much greater.
- CSIS OpEd with Ami Bera (D-CA) and Scott... out in Politico or C...

Other updates:

- Telcom Friday with Brooks staffer. They are... Bera. Now fully briefed on CDC concept and potential implementation model. Clarified... duplicative of USPHS ready reserve corps which is now authorized but not being implemented (to my knowledge) and would be different... etc.
- ... Saturday with CDC COVID-19 Chief Medical Officer. Confirms many are thinking about the workforce issue. Notes that CDC unlikely to "own," but great suggestion to engage CDC... national response discussion... <https://nnptc.org/> with eight CDC...
- FEMA contacts report they are hiring RPCVs... FEMA recruiting email attached.
- Charles shared Vanessa Kerry's OpEd emphasizing same themes: response workforce and jobs. <https://www.bost... disease-team-calls-on-state-to-harness-people-power/>

Next steps:

- Executive – support... to FEMA to increase speed and scale
- Legislation – new appropriations for FEMA or CDC if needed
- News... advocate...
- Demand signal – state and local authorities request
- Implementation and management details working out

Overall goal: Green... COVID-19 Response Corps would be a (big) part of solution. Idea of first order for CDC course...

